Mirum prices $600m convertible notes offering due 2032

Mirum Pharmaceuticals is raising $600 million via 0.00% convertible senior notes due 2032, with up to an additional $90 million available to purchasers, and expects net proceeds of about $583.8 million. About $475 million will be used to exchange roughly $237.2 million of 4.00% convertible notes due 2029, while the balance supports general corporate purposes and possible acquisitions. The financing is modestly positive for balance-sheet flexibility, though recent Q1 revenue of $159.9 million beat estimates while EPS missed sharply due to one-time acquisition-related expenses.

Analysis

This financing is less about capital raising and more about balance-sheet engineering: Mirum is effectively terming out existing conversion overhang while reducing cash coupon burden to zero, which should improve near-term FCF optics and lower refinancing risk. The exchange into longer-dated paper also shrinks the probability of a forced 2029 liquidity event, but it introduces a new equity ceiling because the fresh convert sits close enough to the money that hedging flows can cap upside on strength.

The second-order winner is likely the equity base if management can keep executing on commercial growth; the exchange plus new money buys optionality for tuck-in M&A without immediately pressuring the P&L. The loser is existing common shareholders who now face a larger fully diluted share count and a cleaner path for convert holders to delta-hedge rallies, which often dulls post-deal momentum once the initial “deleveraging” narrative fades.

The key risk is that the market may be overestimating how much this changes fundamental value: the offering improves survivability more than it improves intrinsic earnings power. If the next 1-2 quarters show any slowdown in top-line growth or evidence that acquisition expenses remain sticky, the market can quickly re-rate the stock back toward a lower multiple despite the capital raise. Conversely, if the company deploys the capital into accretive assets, the new convert could look cheap in hindsight because the equity could reprice above the conversion threshold over the next 12-24 months.

Contrarian take: the crowded view is probably that this is a straightforward de-risking event and therefore bullish. In practice, zero-coupon converts often signal management believes the stock is rich enough to finance against, which can be read as a statement that upside is finite near term. That makes the setup more attractive as a financing-arb or relative-value short than as an unqualified long at current levels.

Key Decisions for Investors

• Short-term: fade strength in MIRM into deal completion via a 1-3 week short or put spread, targeting a post-pricing drift lower as convert hedging and dilution concerns get processed; risk is a squeeze if the market treats the financing as a clean de-risking.
• Medium-term: pair long MIRM debt/new converts vs short common equity exposure if borrow is available, capturing the capital structure arbitrage from reduced coupon burden but capped upside in the stock.
• For equity portfolios: avoid chasing MIRM above the recent range until the new share count and use of proceeds are clearer; better entry is after the financing-related vol passes and the stock re-tests support on normal volume.
• If willing to express upside, use call spreads 3-6 months out rather than outright equity; the structure limits premium paid if convert-related supply suppresses the stock for several weeks.
• Watch for a catalyst re-entry only if management announces an accretive acquisition or another quarter of top-line acceleration; that would justify a longer-dated long with a 12-24 month horizon.